FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 356:2073-2081 May 17, 2007 Number 20 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text PowerPoint Slide Set CME Exam Supplementary Material Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear PubMed Citation

Classic preventive vaccines are designed to mimic the effects of natural exposure to microbes. They provide a high level of long-lasting protection against infection in the vast majority of recipients and serve as free-standing preventive measures. Although a classic preventive vaccine remains the ultimate goal of efforts to develop a vaccine for protection against the human immunodeficiency virus (HIV), the enormous genetic diversity and other unique features of the HIV envelope protein have thus far thwarted attempts to identify an effective candidate. However, we have learned from studies of HIV pathogenesis in humans and from animal models that a vaccine . . . [Full Text of this Article]

Obstacles to Vaccine Development

Early Focus on Monomeric Envelope Proteins

T-Cell Immunity in the Control of HIV Infection

T-Cell Vaccines

Complicating Factors

Research Issues

Conclusions

Source Information

From the Division of AIDS (M.I.J.) and the Office of the Director (A.S.F.), National Institute of Allergy and Infectious Diseases, Bethesda, MD.

Address reprint requests to Dr. Fauci at the National Institute of Allergy and Infectious Diseases, 31 Center Dr., MSC 2520, Bldg. 31, Rm. 7A03, Bethesda, MD 20892, or at afauci@niaid.nih.gov.

This article has been cited by other articles:

• Taylor, B. S., Sobieszczyk, M. E., McCutchan, F. E., Hammer, S. M. (2008). The Challenge of HIV-1 Subtype Diversity. NEJM 358: 1590-1602 [Full Text]  
• Balamurugan, A., Lewis, M. J., Kitchen, C. M. R., Robertson, M. N., Shiver, J. W., Daar, E. S., Pitt, J., Ali, A., Ng, H. L., Currier, J. S., Yang, O. O. (2008). Primary Human Immunodeficiency Virus Type 1 (HIV-1) Infection during HIV-1 Gag Vaccination. J. Virol. 82: 2784-2791 [Abstract] [Full Text]  
• Harari, A., Bart, P.-A., Stohr, W., Tapia, G., Garcia, M., Medjitna-Rais, E., Burnet, S., Cellerai, C., Erlwein, O., Barber, T., Moog, C., Liljestrom, P., Wagner, R., Wolf, H., Kraehenbuhl, J.-P., Esteban, M., Heeney, J., Frachette, M.-J., Tartaglia, J., McCormack, S., Babiker, A., Weber, J., Pantaleo, G. (2008). An HIV-1 clade C DNA prime, NYVAC boost vaccine regimen induces reliable, polyfunctional, and long-lasting T cell responses. J. Exp. Med. 205: 63-77 [Abstract] [Full Text]  
• Steinbrook, R. (2007). One Step Forward, Two Steps Back -- Will There Ever Be an AIDS Vaccine?. NEJM 357: 2653-2655 [Full Text]  
• Butler, N. S., Dandekar, A. A., Perlman, S. (2007). Antiviral Antibodies Are Necessary To Prevent Cytotoxic T-Lymphocyte Escape in Mice Infected with a Coronavirus. J. Virol. 81: 13291-13298 [Abstract] [Full Text]  
• Peut, V., Kent, S. J. (2007). Utility of Human Immunodeficiency Virus Type 1 Envelope as a T-Cell Immunogen. J. Virol. 81: 13125-13134 [Abstract] [Full Text]  
• Tonks, A. (2007). Quest for the AIDS vaccine. BMJ 334: 1346-1348 [Full Text]